Lung Cancer News

The FDA granted breakthrough therapy designation to mobocertinib for treatment of certain patients with metastatic non-small cell lung cancer.

Prophylactic cranial irradiation did not extend OS among a cohort of patients with limited-stage small cell lung cancer, according to results of a propensity-matched analysis published in JAMA Network Open.

First-line treatment with carboplatin plus pemetrexed followed by maintenance pemetrexed appeared noninferior to docetaxel monotherapy in extending OS among older patients with advanced nonsquamous non-small cell lung cancer, according to results of a randomized phase 3 trial published in JAMA Oncology.

Amid the COVID-19 pandemic, it is important to pay close attention to individual clinical and radiological pulmonary signs of patients with lung cancer while awaiting specific evidence-based treatment guidelines.

Public-facing websites of cancer screening programs in the United States often fail to present balanced information about the possible benefits and harms of screening, according to an analysis published in the Annals of Internal Medicine.

First-line pembrolizumab in combination with pemetrexed and platinum-based chemotherapy substantially extended PFS and OS among patients with metastatic nonsquamous non-small cell lung cancer, according to an updated analysis of the randomized phase 3 KEYNOTE-189 study published in Journal of Clinical Oncology.

Pembrolizumab in combination with docetaxel substantially improved overall response rate and PFS compared with docetaxel alone among patients with non-small cell lung cancer whose disease progressed after platinum-based chemotherapy, according to results of a randomized phase 2 study published in JAMA Oncology.

The addition of tislelizumab to first-line chemotherapy extended PFS among patients with nonsquamous non-small cell lung cancer, according to topline data from a randomized phase 3 trial released by the agent’s manufacturer.

Osimertinib demonstrated “overwhelming efficacy” for the adjuvant treatment of patients with stage IB, II and IIIA epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection, according to a press release issued by the agent’s manufacturer.

The FDA granted priority review to nivolumab plus ipilimumab combined with a limited chemotherapy course as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer.